microLIQUID will be pleasured to meet you at Compamed 2018 on November 12-15 in Düsseldorf. We will be at Hall 8a/F34.1.
OEM & ODM of Microfluidic Cartridges and Instruments, IVD & Bioscience and Cell Culture have been our main commitment areas over the last few years. With capabilities spanning the entire value chain, microLIQUID has become a one-stop provider of Bioscience solutions.
Starting with design and proof of concept, we work with our company partners from development to mass-production of potentially fully certified IVD or Pharma products.
We offer full solutions with capabilities to integrate different technologies in developments with a microfluidics core, becoming more than just a microfluidics company. Looking at our customers necessities, we have reinforced ourselves including a bioscience department, automated instrumentation and equipment, offering higher quality and faster services than the competence thanks to these resources.
We detected the need from the customer and we have evolved to offer the required complete service. Our OEM & ODM microfluidic cartridge technologies fit the demand for improving the efficiency of techniques applied in medical devices for diagnostics, drug delivery and drug discovery. Because of our focus in these sectors, we work on how our microfluidic technology could interface with and provide improvements for current workflows, assaying techniques etc.
At Compamed 2018, we would love to have an opportunity to demonstrate our latest offerings and technologies to you in depth as microLIQUID has grown over the last few months.
See you there!
World Osteoporosis Day takes place every year on October 20.
Because of the ageing of the society, osteoporosis (
Currently, osteoporosis is commonly known as a “silent killer” disease. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. Until now little or no measures for prevention or early detection of this disease are taken, because no simple, yet sufficiently precise or sensitive tools for early detection of individuals at risk of osteoporosis are available, there is a need to develop a efficient rapid diagnostics test to detect the disease.
At microLIQUID we are proud to be able to help with our expertise in microfluidic IVD system development in this cause by being part of PoCOsteo. We are working hand in hand together with European leaders, both from academia and industry, to develop new POC applications by using the latest microfluidic technologies applied to diagnostics.
The overall objective of the currently proposed PoCOsteo project is a IVD Point-of-care development. Also, the clinical validation and preparation for commercialization of thePoint-of-Care tool for bone disease. The osteoporosis prevention, osteoporosis detection and osteoporosis treatment is our aim.
We are showcasing our latest offerings and technologies, and our top product experts are there on hand to answer your questions.
See you there!!!
microLIQUID will be at Biospain 2018 this September 25-27 in Seville, Spain. We will be there together with the Basque Health Cluster.
For over 10 years, microLIQUID has provided the best services for Microfluidic Cartridge Manufacturing, Automated Instrumentation and IVD and Bioscience Services.
With capabilities spanning the entire value chain, microLIQUID has become a one-stop provider of end-to-end Bioscience solutions. Starting with design and proof of concept, we work with our company partners from development to mass-production of potentially fully certified IVD or Pharma products.
We would love to have an opportunity to demonstrate our latest offerings and technologies to you in depth as microLIQUID has grown over the last few months.
Many thanks for your time and we look forward to hearing from you!
It has been our great pleasure to interview Iñaki Ochoa, head of the Research Group with which we collaborate to develop the latest technologies in Cell Culture.
It is a group specialized in oncology; that is, they perform treatments for cancer. The group is known for having developed the most advanced model in the world of glioblastoma; one of the most dangerous cancers.
Let´s see what he has to tell us!
microLIQUID: Problems encountered with conventional Cell Culture methods, and the solutions offered by Microfluidic Cell Culture:
Iñaki Ochoa: The conventional Cell Culture methods that are used today are based mainly on two-dimensional cultures performed on plastic plates. The cells are placed or “planted” at the bottom of these plates. To provide them with nutrients, a liquid, or culture medium, is added on top of them. This liquid provides the necessary nutrients. These plates require a gaseous connection to the outside in order to access the essential gases (such as oxygen) to maintain viable cells. As can easily be concluded, our body is not two-dimensional, nor do our cells live in isolatiom from each other. Under current culture conditions, the cells lack an environment similar to that of our body. Cells in the laboratory do not grow under three-dimensional conditions, they have an excess of essential elements (nutrients, oxygen, etc.) and, in addition, they lack interaction with other cell types for in vivo communication.
microLIQUID: Advantage of the Microfluidic Cell Culture:
For another year, microLIQUID will be exhibiting at AACC 2018 (Annual Scientific Meeting & Clinical Lab Expo) which will take place at McCormick Place, Chicago, IL, USA (July 31-August 2).
On behalf of our company, if you are attending to the event, we want to take advantage to have a meeting with you in order to talk about our common interests.
See you soon!
The use of durable replica moulds with high-feature resolution has been proposed as an inexpensive and convenient route for the manufacture of microstructured materials. A simple and fast duplication method, it involves the use of a master mould to create durable polymer replicas, using polydimethylsiloxane (PDMS). The application of PDMS offers numerous advantages due to its intrinsic properties such as its biocompatibility, affordable price, transparency (240nm-1100nm) as well as its low autofluorescence. The replica process enables fast and easy manufacturing since it can be covalently stuck to a glass substrate, using plasma treatment to form sealed microfluidic devices. The replica process is clean and precise, while multiple replications can be obtained from one master. This dramatically decreases both the expenditure and the time required to create specific patterns that need to be used consistently in the creation of various devices.
microLIQUID manufactures polymer SU-8 master moulds on silicon wafers, which are widely used to produce microfluidic disposables in the development and prototyping stage. In addition, we generate series of PDMS copies with excellent reproducibility and precision. microLIQUID offers high resolution moulds with a standard deviation of under 2%. microLIQUID is working in applications such as droplet generation for PCR diagnostics, single-cell analysis and high throughput screening among others. The moulds are highly reusable since we offer several treatments to increase the service life of the mould. This replica method will help you choose the optimum design for your product prior to scaling up to mass production. Indeed, more than 50 companies all over the world have already done so.
The company is now celebrating a decade working on the design and manufacture of novel microfluidic products for our customers; we are proud and delighted to have made it this far, and excited about the future!
During this time, we´ve grown in many ways, for example by increasing the number of employees and clients, as well as boosting revenues. We have collaborated successfully in more than 300 microfluidic projects around the world, doubling our turnover since 2014 and we have gained vast experience in this business dimension. In addition, we develop new value propositions to our customers, offering unique complete value chain solutions from complex microfluidic consumables that can be processed on our own design automated instrumentation (e.g. Point of Care instruments).
Since its establishment, microLIQUID has focused on delivering quality to its customers and fulfilling their expectations. This is the reason why so many of our clients and partners trust our professionalism and appreciate the individual approach we provide.
We are grateful to all those who have worked with us and have helped us over these last 10 years to develop our company. microLIQUID´s success would not have come to fruition had it not been for their unwavering support.
We are optimistic about what lies ahead and are very confident that we will be able to help many more future customers around the world to manufacture solutions based on our microfluidics and automated instrument solutions in fields such as rapid testing, immuno-oncology, NGS and Precision medicine, liquid biopsy and drug delivery among others.
microLIQUID has shown once again that it strives to develop new point-of-care platforms by using the latest technologies in microfluidics.
In this project, microLIQUID will be working together with European leaders, both from academia and industry, to develop new PoC applications.
We invite you to read the press release issued by Ghent University at the start of the project in October 2017.
“Ghent, Belgium – October 1, 2017 – Ghent University and its project partners today announced the launch of the PoCOsteo project. Together they will develop and validate a point-of-care in-office device for identifying individuals at high risk of osteoporosis and osteoporotic fracture. The project is supported by the European Union’s Horizon 2020 Framework Programme for Industrial leadership in nanotechnologies, advanced materials, biotechnology and advanced manufacturing and processing (H2020-NMBP). The overall goal of the project is the development, clinical validation and preparation for commercialisation of a point-of-care tool for bone disease (a.o. osteoporosis) prevention, detection and treatment.
Indeed, as a consequence of the ageing of the society, osteoporosis (literally “porous bone”) and its complications is becoming more and more prevalent, making the bone disease a health priority in many parts of the world. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. This causes a serious burden for the patient and a high medical care cost for the society. Currently osteoporosis is commonly known as a “silent killer” disease. Up to 20% of patients die in the first year following a hip fracture, mostly due to pre-existing medical conditions. Less than half of those who survive the hip fracture regain their previous level of function1. Early detection of individuals at risk of osteoporosis and starting a suitable treatment before fractures and complications arise would drastically improve the current situation. Until now little or no measures for prevention or early detection of osteoporosis are taken, because no simple, yet sufficiently accurate or sensitive tools for early detection are available.
The PoCOsteo system will employ electrochemical detection and brings together proteomics, genomics and microfluidics technologies. The in-office test will provide the results in real-time during consultation and can be performed by unskilled technicians even at rural areas where access to current state-of-the-art equipment is limited. The design will limit the amount of both expensive reagents and blood samples needed for the tests and so it not only reduces the cost of each test, which is of great importance, especially nowadays when full reimbursement is not practiced in many countries, but also reduces the patient’s pain and discomfort.
The project will be supported and advised by the IOF, the International Osteoporosis Foundation, which is the main global alliance of patient societies, research organizations, healthcare professionals and international companies working to promote bone, muscle and joint health.
Over the next four years, PoCOsteo will be coordinated by Ghent University. Industrial, academic and clinical partners will bring their expertise to the project: Universitat Rovira I Virgili and microLIQUID (Spain), Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung (Germany), Labman Automation (United Kingdom), Medizinische Universität Graz (Austria), Endocrinology and Metabolism Research Institute (Iran) and Fundico (Belgium).”